by Pete Celano | Nov 16, 2025 | Uncategorized
Naltrexone and Acamprosate are widely used to treat alcohol use disorder (AUD)– Naltrexone: Associated with a greater cumulative number of days of abstinence, fewer drinks, and less severe craving. Studies have shown it can be safe in patients with cirrhosis,...
by Pete Celano | Nov 11, 2025 | Uncategorized
Here’s what transpired at the annual AASLD The Liver Meeting® 2025 (Washington DC) for Day #4, 11/10/2025 — Programming highlights Morning sessions included the State-of-the-Art Lecture, major general hepatology updates, and “Meet the Experts” (MTE) format sessions....
by Pete Celano | Nov 10, 2025 | Uncategorized
Here’s what transpired at the annual AASLD The Liver Meeting® 2025 (Washington DC) for Day #3, 11/09/2025 — Key Sessions & Focus Areas The “Hepatology Associates Course, Part 1: Hepatology Associates as Leaders in Multidisciplinary Care” ran from 8:00...
by Pete Celano | Nov 9, 2025 | Uncategorized
Here’s what transpired at the annual AASLD The Liver Meeting® 2025 (Washington DC) for Day #2, 11/08/2025 — Key sessions & programs A full-day poster session ran from 8:00 a.m.–5:00 p.m. in Hall DE. Topics included diagnostics & biomarkers for...
by Pete Celano | Nov 7, 2025 | Uncategorized
Here are two key new trial-data disclosures from the annual AASLD The Liver Meeting® 2025 (Washington DC) for Day #1, 11/07/2025 — 1. Akero Therapeutics — Data from the Phase 2b “SYMMETRY” & “HARMONY” trials of Efruxifermin in MASLD/MASH Akero announced new...
